Biotechnology startup GentiBio on Wednesday struck a deal with Bristol Myers Squibb to develop a cell therapy for inflammatory bowel disease — the latest sign of the pharmaceutical industry’s interest in an emerging field of drug research.
GentiBio, Inc., a biotherapeutics company developing engineered regulatory T cells (Tregs) therapies for autoimmunity, autoinflammation and allergic...